Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cytokinetics (CYTK)
Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,634,358
  • Shares Outstanding, K 95,641
  • Annual Sales, $ 94,590 K
  • Annual Income, $ -388,960 K
  • 60-Month Beta 0.80
  • Price/Sales 39.06
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CYTK with:

Options Overview Details

View History
  • Implied Volatility 56.78% ( +1.73%)
  • Historical Volatility 37.60%
  • IV Percentile 4%
  • IV Rank 13.83%
  • IV High 104.83% on 10/06/22
  • IV Low 49.07% on 06/01/23
  • Put/Call Vol Ratio 0.05
  • Today's Volume 91
  • Volume Avg (30-Day) 111
  • Put/Call OI Ratio 1.70
  • Today's Open Interest 6,639
  • Open Int (30-Day) 7,520

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -1.25
  • Number of Estimates 9
  • High Estimate -1.03
  • Low Estimate -1.43
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -443.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.19 +4.24%
on 05/17/23
41.24 -8.51%
on 05/23/23
-1.71 (-4.34%)
since 05/05/23
3-Month
32.96 +14.47%
on 03/24/23
41.24 -8.51%
on 05/23/23
-1.40 (-3.58%)
since 03/06/23
52-Week
32.96 +14.47%
on 03/24/23
55.80 -32.38%
on 09/09/22
-1.68 (-4.26%)
since 06/06/22

Most Recent Stories

More News
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 37.73 (-0.71%)
GERN : 3.60 (-0.55%)
Cytokinetics: Q1 Earnings Snapshot

Cytokinetics: Q1 Earnings Snapshot

CYTK : 37.73 (-0.71%)
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline

Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

URGN : 10.49 (+9.38%)
CYTK : 37.73 (-0.71%)
Cytokinetics (CYTK) Dips 20% so Far in 2023 on Setbacks

Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv mecarbil.

NVO : 160.76 (+1.84%)
LGND : 72.50 (+2.11%)
CYTK : 37.73 (-0.71%)
Want Diversified Upside in Biotechnology? Check out LABU

Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.

XBI : 88.12 (+1.63%)
CYTK : 37.73 (-0.71%)
LABU : 7.08 (+4.27%)
MDGL : 273.83 (+2.74%)
ARWR : 36.12 (+3.20%)
LABD : 12.31 (-4.57%)
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

Sector ETF report for PSCH

PSCH : 133.47 (+1.47%)
AMN : 102.72 (+2.98%)
CYTK : 37.73 (-0.71%)
XLV : 129.70 (-0.83%)
VHT : 240.28 (-0.62%)
ENSG : 93.38 (+2.00%)
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -18.85% and 73.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 37.73 (-0.71%)
LQDA : 8.59 (-2.16%)
Cytokinetics: Q4 Earnings Snapshot

Cytokinetics: Q4 Earnings Snapshot

CYTK : 37.73 (-0.71%)
Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback

Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.

REGN : 748.14 (-0.28%)
INCY : 61.71 (-1.06%)
MRNA : 126.90 (-1.55%)
CYTK : 37.73 (-0.71%)
Is a Surprise Coming for Cytokinetics (CYTK) This Earnings Season?

Cytokinetics (CYTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CYTK : 37.73 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 39.54
2nd Resistance Point 39.16
1st Resistance Point 38.45
Last Price 37.73
1st Support Level 37.36
2nd Support Level 36.98
3rd Support Level 36.27

See More

52-Week High 55.80
Fibonacci 61.8% 47.08
Fibonacci 50% 44.38
Fibonacci 38.2% 41.68
Last Price 37.73
52-Week Low 32.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar